United Therapeutics Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From United Therapeutics Corporation
Amryt’s birch bark extract oleogel-S10 for Epidermolysis Bullosa patients might become only the third botanical drug to clear the FDA.
Helped by its convenient five-day dosing, the shortest of any topical treatment for the precancerous skin disease, the Spanish company believes Klisyri, already launched in the US, will become a popular alternative to current options for actinic keratosis.
The firms hope academic research can yield first-in-class therapies and spinout companies. Also, Yale unveils research alliances with three biotechs.
BMS is impressed with Exscientia's projects with recently acquired Celgene and has signed up to use the UK firm's artificial intelligence platform to accelerate the discovery of small molecules in areas including oncology and immunology.
- Large Molecule
- Other Names / Subsidiaries
- Lung Biotechnology PBC
- Lung Rx, Inc.
- SteadyMed Ltd.
- SteadyMed Therapeutics, Inc.
- Unither Pharmaceuticals
- Unither Virology